Description

We are thrilled to announce the launch of DIAQUIL, a pioneering product specifically formulated to treat Non-Healing Diabetic Foot Ulcers (NHDFU). At Hetero Healthcare, our unwavering commitment is to improve the lives of those suffering from diabetic foot complications by offering innovative treatments that can prevent limb amputation and enhance the quality of life.

Introducing DIAQUIL: A Breakthrough in NHDFU Treatment

DIAQUIL represents a major leap forward in the management of Diabetic Foot Ulcers. This cutting-edge product features a patented formulation that uniquely targets and regulates Metallo Proteinase activity to prevent the breakdown of the extracellular matrix. By doing so, DIAQUIL not only accelerates the healing process but also promotes tissue regeneration, offering renewed hope for patients who have long battled with these challenging and often debilitating ulcers.

Changing the Narrative for NHDFU Patients

Our goal with DIAQUIL is to shift the paradigm of NHDFU treatment. We aim to reduce the need for amputations and empower patients to reclaim their health and independence. DIAQUIL provides a promising new option for those whose lives have been significantly affected by diabetic foot ulcers, offering a chance for healing and a better quality of life.

Join Us in Our Mission to Transform Patient Care

We invite healthcare professionals, caregivers, and stakeholders to join us in this vital mission. Together, we can make a substantial difference in the lives of patients with diabetic foot ulcers, improving outcomes and delivering hope.

For more information about DIAQUIL and how you can partner with us to enhance patient care, please visit our website or contact us directly.